MYSM1 promotes lung adenocarcinoma progression via TRAF2/3-mediated activation of MAPK and non-canonical NF-κB pathways
9.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-10-29 23:42
摘要：
MYSM1, a deubiquitinating enzyme, is significantly overexpressed in lung adenocarcinoma (LUAD) and correlates with poor patient prognosis. It enhances LUAD cell proliferation and migration by interacting with TRAF2 and TRAF3, leading to the activation of MAPK and non-canonical NF-κB signaling pathways. This study identifies MYSM1 as a potential prognostic biomarker and therapeutic target, emphasizing the need for novel strategies in treating lung cancer.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分=2.0分
business_impact
1.0分+1.0分=2.0分
scientific_rigor
1.5分+1.5分=3.0分
timeliness_innovation
1.5分+1.5分=3.0分
investment_perspective
2.5分+2.5分=5.0分
market_value_relevance
1.0分+1.0分=2.0分
team_institution_background
0.5分+0.5分=1.0分
technical_barrier_competition
1.0分+1.0分=2.0分
关键证据
MYSM1 is markedly overexpressed in lung adenocarcinoma and correlates with advanced disease stage and poor prognosis.
MYSM1 promotes LUAD cell proliferation and migration in vitro and in vivo.
MYSM1 interacts with TRAF2 and TRAF3, enhancing their stability and activating oncogenic signaling pathways.
真实性检查
否
AI评分总结
MYSM1, a deubiquitinating enzyme, is significantly overexpressed in lung adenocarcinoma (LUAD) and correlates with poor patient prognosis. It enhances LUAD cell proliferation and migration by interacting with TRAF2 and TRAF3, leading to the activation of MAPK and non-canonical NF-κB signaling pathways. This study identifies MYSM1 as a potential prognostic biomarker and therapeutic target, emphasizing the need for novel strategies in treating lung cancer.